Featured Press Releases

Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease

Teva and Sanofi Announce Accelerated Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

  • 28 May 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

Aptamer Sciences Inc.Innovative Liver Cancer Treatment AST-201

Aptamer Sciences Inc.Innovative Liver Cancer Treatment AST-201

Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors

Psilera Welcomes Biopharma Executive Dr. Magali Haas to its Board of Directors

Bruker Acquires Majority Stake in RECIPE, a Leader in Mass Spectrometry-Based Diagnostic Assays for Therapeutic Drug Monitoring

Bruker Acquires Majority Stake in RECIPE, a Leader in Mass Spectrometry-Based Diagnostic Assays for Therapeutic Drug Monitoring

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.